German multinational pharmaceutical and life sciences company Bayer AG (ETR:BAYN) has opened a new Research and Innovation Center in the United States, the company announced on Wednesday.
Located at Kendall Square in Boston-Cambridge, Massachusetts, this 62,100 sq ft facility houses a new centre of precision molecular oncology research equipped with state-of-the-art laboratories and offices for the development of novel targeted cancer therapies.
In addition, a newly established research team will focus on leveraging chemical biology techniques to further advance the company's oncology drug development process.
Bayer's investment in the new facility amounts to USD140m.
Boston-Cambridge is home to approximately 1,000 biotechnology companies, with Kendall Square being the centre of pharmaceutical innovation on the East Coast of the US, Bayer said. The company is now present in four of the largest biotechnology hubs in the country: Boston, San Francisco, San Diego and Research Triangle Park, North Carolina.
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories